Related Experiment Video
Updated: Jan 28, 2026

RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue
Published on: August 2, 2014
Inhibition of human cytomegalovirus major capsid protein expression and replication by ribonuclease P-associated
Qiudi Deng1, Yujun Liu2,3, Xin Li1
1Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China.
Abstract:
External guide sequences (EGSs) signify the short RNAs that induce ribonuclease P (RNase P), an enzyme responsible for processing the 5' termini of tRNA, to specifically cleave a target mRNA by forming a precursor tRNA-like complex. Hence, the EGS technology may serve as a potential strategy for gene-targeting therapy. Our previous studies have revealed that engineered EGS variants induced RNase P to efficiently hydrolyze target mRNAs. In the present research, an EGS variant was designed to be complementary to the mRNA coding for human cytomegalovirus (HCMV) major capsid protein (MCP), which is vital to form the viral capsid. In vitro, the EGS variant was about 80-fold more efficient in inducing human RNase P-mediated cleavage of the target mRNA than a natural tRNA-derived EGS. Moreover, the expressed variant and natural tRNA-originated EGSs led to a decrease of MCP expression by 98% and 73%-74% and a decrease of viral growth by about 10,000- and 200-fold in cells infected with HCMV, respectively. These results reveal direct evidence that the engineered EGS variant has higher efficiency in blocking the expression of HCMV genes and viral growth than the natural tRNA-originated EGS. Therefore, our findings imply that the EGS variant can be a potent candidate agent for the treatment of infections caused by HCMV.
Insights
Engineered external guide sequences (EGSs) efficiently target and degrade human cytomegalovirus mRNA, significantly reducing viral growth. This EGS variant shows promise as a novel gene-targeting therapy for HCMV infections.
Area of Science:
- Molecular Biology
- Virology
- Biotechnology
Background:
- External guide sequences (EGSs) are short RNAs that direct ribonuclease P (RNase P) to cleave specific mRNAs.
- EGS technology offers potential for gene-targeting therapies.
- Previous studies demonstrated engineered EGS variants can effectively hydrolyze target mRNAs.
Purpose of the Study:
- To design and evaluate an EGS variant targeting the mRNA of human cytomegalovirus (HCMV) major capsid protein (MCP).
- To assess the efficiency of the engineered EGS variant in inhibiting HCMV gene expression and viral replication.
Main Methods:
- An EGS variant complementary to HCMV MCP mRNA was designed.
- In vitro assays measured RNase P-mediated mRNA cleavage efficiency.
- Cell-based experiments assessed MCP expression and viral growth reduction.
Main Results:
- The engineered EGS variant was 80-fold more efficient than natural tRNA-derived EGS in cleaving HCMV MCP mRNA in vitro.
- In cells, the EGS variant reduced MCP expression by 98% and viral growth by 10,000-fold.
- Natural tRNA-originated EGS reduced MCP expression by 73-74% and viral growth by 200-fold.
Conclusions:
- Engineered EGS variants demonstrate superior efficiency in inhibiting HCMV gene expression and viral growth compared to natural tRNA-derived EGS.
- The developed EGS variant is a potent candidate for treating HCMV infections.
More Related Videos
Related Concept Videos
Chromosome Replication
DNA Replication
Replication in Prokaryotes
DNA replication...
Replication in Prokaryotes
Cis-regulatory Sequences
The DNA Replication Fork
Collagens are the Major Structural Proteins of ECM
Connective tissue proper includes loose...

